Search Results

GeneCentric Therapeutics today announced upcoming presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 31st to June 4th.

GeneCentric Therapeutics today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

GeneCentric Therapeutics today announced the appointment of Prasanth Reddy, MD, MPH, FACP, and Don Hardison as independent directors of its Board of Directors.

GeneCentric Therapeutics today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California.

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that its PurIST℠ test is now commercially available through Tempus for clinical use.

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.

GeneCentric Therapeutics announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp.

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center.